Autoimmune Conditions and Primary CNS Lymphoma Risk
Primary central nervous system lymphoma (PCNSL) is a rare (incidence rate of 0.6 cases per 100,000 person years) non-Hodgkin lymphoma (NHL) found in the brain, spinal cord, and leptomeninges.
CNS Cancers
Addition of Bevacizumab to Temozolomide-Based Chemotherapy Increased OR in Children With R/R Neuroblastoma
The addition of bevacizumab to temozolomide-based chemotherapy was also associated with higher rates of grade 3 or higher thrombocytopenia and anemia.
Bing-Neel Syndrome: Managing Patients With Waldenström Macroglobulinemia Characterized by CNS Involvement
According to the authors, treatment of patients with Bing-Neel syndrome should involve the use of CNS-penetrating approaches.
Ribociclib Shown to Penetrate the Blood-Brain Barrier in Glioblastoma
A phase 0 study of ribociclib in patients with recurrent glioblastoma seeks to inform the feasibility of the use of CDK 4/6 inhibitors for deadly brain tumors.
Treatment Reduction in Intermediate-Risk Neuroblastoma Deemed Successful
For specific subsets of patients with intermediate-risk neuroblastoma, an algorithm successfully reduced treatment while maintaining survival outcomes.
Outcomes Poor Years After Radiation for Pediatric Glioma Survivors
Survivors of childhood low-grade gliomas treated with radiotherapy have poorer neuropsychological and socioeconomic-status (SES) outcomes.
LIBRETTO-121: A Phase 1/2 Trial Investigating LOXO-292 in Pediatric Patients With Advanced Solid or Primary CNS Tumors
A primary outcome measure for phase 1 of the trial is determining the safety of oral LOXO-292.
Computer-Assisted Diagnosis Aids Detection of Glioma Growth
Computer-assisted diagnosis (CAD) can help physicians detect growth of low-grade gliomas.
Entrectinib Shows Activity in Pediatric Brain Tumors and Other Solid Tumors
Entrectinib showed activity and appeared to be safe in pediatric patients with recurrent or refractory solid tumors harboring NTRK1/2/3, ROS1, or ALK aberrations.
Phase 3 Study of Investigative Glioblastoma Tx Halted
AbbVie has halted enrollment in all ongoing studies of depatuxizumab mafodotin, after an Independent Data Monitoring Committee (IDMC) recommended a phase 3 study of the treatment be stopped due to a lack of survival benefit.
